Invention Grant
- Patent Title: Combinations of AKT inhibitor compounds and erlotinib, and methods of use
-
Application No.: US14836827Application Date: 2015-08-26
-
Publication No.: US09610289B2Publication Date: 2017-04-04
- Inventor: Michelle Nannini , Deepak Sampath
- Applicant: Genentech, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: GENENTECH, INC.
- Current Assignee: GENENTECH, INC.
- Current Assignee Address: US CA South San Francisco
- Agency: Viksnins Harris & Padys PLLP
- Main IPC: A61K31/505
- IPC: A61K31/505 ; A61K31/517 ; C07D239/70 ; A61K31/437 ; A61K31/496 ; A61K31/58 ; A61K31/282 ; A61K31/337 ; A61K31/4188 ; A61K31/4745 ; A61K31/513 ; A61K31/519 ; A61K31/704 ; A61K39/395 ; C07D403/12 ; A61K31/436 ; A61K31/138 ; A61K31/4166 ; A61K31/495 ; A61K31/555 ; A61K31/7068 ; C07K16/40 ; A61K39/00
Abstract:
The invention provides A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
Public/Granted literature
- US20160051550A1 COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ERLOTINIB, AND METHODS OF USE Public/Granted day:2016-02-25
Information query
